NeuroOne Medical Technologies Corporation reported fiscal Q1 2026 financial results with product revenue of $2.9 million, net loss of $1.4 million or ($0.03) per share, and cash of $3.6 million as of December 31, 2025. The company expects at least $10.5 million in product revenue for fiscal year 2026 and highlighted FDA clearance for OneRF Trigeminal Nerve Ablation System with nine successful cases.
Key takeaways
Product revenue $2.9 million in Q1 FY2026 vs $3.3 million same quarter prior year and $2.7 million prior quarter
Net loss $1.4 million or ($0.03) per share in Q1 FY2026 vs net income $1.8 million or $0.06 per share prior year
Expects product revenue at least $10.5 million in FY2026 vs $9.1 million in FY2025
FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System; completed nine cases with all patients reportedly pain free
Nearly 50% of all ablations since OneRF Ablation System launch in 2024 performed in Q1 FY2026
Cash and equivalents $3.6 million as of December 31, 2025; no debt outstanding
Appointed Jason Mills to Board of Directors in December 2025